BioLineRx’s Stem Cell Mobilization Therapy BL-8040 to Enter Phase 3 Trial
BioLineRx is seeking regulatory approval to advance into a Phase 3 clinical trial its treatment BL-8040, for blood stem cell mobilization to prepare for autologous…
News
Kite Pharma Asks FDA to Pave Way Toward It Holding Clinical Trials of Its Myeloma Therapy KITE-585
Kite Pharma has submitted an investigational new drug application to the U.S. Food and Drug Administration that would pave the way toward clinical trials of its…
Scottish Medicines Consortium Approves Kyprolis-Dexamethasone Combo for Previously Treated Multiple Myeloma Patients
Combining the proteasome inhibitor Kyprolis (carfilzomib) with dexamethasone is beneficial for adult patients with multiple myeloma who have received…
Cellectar’s CLR 131 Shows Early Promising Survival Outcomes in Phase 1 Trial of Relapsed or Refractory Myeloma
Myeloma patients who received a single dose of the investigational therapy CLR 131 in an ongoing Phase 1 clinical trial have reached a median overall…
Myeloma Patients Who Receive the Maintenance Therapy Revlimid Live Longer, Study Shows
Newly diagnosed multiple myeloma patients who use Revlimid (lenalidomide) as a maintenance therapy after a stem cell transplant live significantly longer than those receiving a placebo…
PharmaMar Launches Aplidin Quadruple Combo Trial in Myeloma
PharmaMar is launching a clinical trial to explore its investigational therapy Aplidin (plitidepsin) in a quadruple combination treatment for multiple myeloma. The four compounds involved…
VAX-DC/MM Cell Therapy Shows Promise in Relapsed or Refractory Myeloma, Lymphoma Patients
NantKwest’s Vax-DC/MM cell therapy has induced a partial or complete response in 42 percent of relapsed or refractory multiple myeloma (MM) and lymphoma patients in a…
Imbruvica Becomes 1st FDA-Approved Therapy for Graft-Versus-Host-Disease in Adults
The U.S. Food and Drug Administration (FDA) has approved Imbruvica (ibrutinib) for the treatment of chronic graft-versus-host-disease (cGVHD), a common complication of stem cell or bone…
STRO-001 Eliminates or Slows Growth of Myeloma and Lymphoma in Mice, Studies Show
Sutro Biopharma‘s STRO-001 eliminates or significantly slows the growth of non-Hodgkin lymphoma and multiple myeloma tumors, studies in mice indicate. Sutro expects the results to support…
Revlimid Therapy May Delay Myeloma Progression and Increase Survival
Revlimid (lenalidomide) therapy maintenance has been shown to delay disease progression and extend survival in newly diagnosed multiple myeloma (NDMM) patients who receive a transplant…
